Top Story Today
Pfizer's China-Licensed Cancer Drug Went From Licensing Deal to Phase 3 in About a Year. That's Basically Unheard Of.
About a year from signing a $1.25 billion licensing deal to having Phase 3 trials ready to launch. That's how fast Pfizer moved on SSGJ-707, a bispecific antibody that blocks both PD-1 and VEGF (two key tumor survival tricks) in a single molecule. Early Phase 2 data showed response rates as high as 81.3% in lung cancer patients. The drug is part of a $20 billion-plus industry land grab for PD-1/VEGF bispecifics, kicked off after a rival became the first drug ever to beat Keytruda head-to-head last year. Pfizer is running two pivotal trials in 2026, with domestic manufacturing already locked in.
Why it matters: With Keytruda's $29.5 billion revenue throne suddenly looking vulnerable and the PD-1 patent cliff approaching around 2028, every major pharma company needs a next-generation immunotherapy. Pfizer's unprecedented speed signals this isn't just another pipeline addition; it's a cornerstone of the company's entire post-COVID oncology rebuild.
Read more →Survival Mode
The Biotech Worth Less Than a House That's Betting Everything on One More Trial
Vistagen's stock once surged over 1,000% on promising data for its anxiety nasal spray, then cratered 80% in a single day when the next Phase 3 flopped. Now the company has cut 20% of its staff and trades under $1. One final Phase 3 (PALISADE-4) is expected in the first half of 2026: positive data could resurrect the company, while another miss likely writes its obituary.
Read more →112 Employees, One FDA Decision, and a Cash Runway That Expires on Contact
Inovio slashed its workforce to 112 people (roughly one Chipotle's worth of staff) and pinned its entire future on an October FDA decision for INO-3107, a DNA-based treatment for recurring throat growths caused by HPV. The company has $58.5 million in cash, burns about $22 million per quarter, and the FDA has already expressed skepticism about its accelerated approval bid. If the answer is no, there's no Plan B.
Read more →